Success Metrics

Active Trials
3(75%)

Phase Distribution

Ph phase_1
1
25%
Ph phase_2
2
50%
Ph not_applicable
1
25%

Phase Distribution

1

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

4

all time

Status Distribution
Active(4)

Detailed Status

Recruiting3
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
3
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 11 (25.0%)
Phase 22 (50.0%)
N/A1 (25.0%)

Trials by Status

not_yet_recruiting125%
recruiting375%

Recent Activity

3 active trials
Showing 4 of 4
not_yet_recruitingnot_applicable

JS212 in Combination With JS111 as First-Line Treatment in EGFR-Mutant Advanced NSCLC

NCT07714304
recruitingphase_1

A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects With Advanced Malignant Solid Tumour

NCT06888830
recruitingphase_2

Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors

NCT07480733
recruitingphase_2

A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer

NCT07309276

Clinical Trials (4)

Showing 4 of 4 trials
NCT07714304Not Applicable

JS212 in Combination With JS111 as First-Line Treatment in EGFR-Mutant Advanced NSCLC

Not Yet Recruiting
NCT06888830Phase 1

A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects With Advanced Malignant Solid Tumour

Recruiting
NCT07480733Phase 2

Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors

Recruiting
NCT07309276Phase 2

A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer

Recruiting

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4